Hormone Receptor, HER2/NEU and EGFR Expression in Ovarian Carcinoma - is here a Prognostic Phenotype?

Demir, Lutfiye; Yigit, Seyran; Sadullahoglu, Canan; Akyol, Murat; Cokmert, Suna; Kucukzeybek, Yuksel; Alacacioglu, Ahmet; Cakalagaoglu, Fulya; Tarhan, Mustafa Oktay

추천

검색

자료유형: 학술저널

저자정보: Demir, Lutfiye (Department of Medical Oncology, Ataturk State Hospital) Yigit, Seyran (Department of Pathology, Ataturk Training and Research Hospital, Katip Celebi University) Sadullahoglu, Canan (Department of Pathology, Ege University) Akyol, Murat (Department of Medical Oncology, Ataturk Training and Research Hospital, Katip Celebi University) Cokmert, Suna (Department of Basic Oncology, Institute of Oncology, Dokuz Eylul University) Kucukzeybek, Yuksel (Department of Medical Oncology, Ataturk Training and Research Hospital, Katip Celebi University) Alacacioglu, Ahmet (Department of Medical Oncology, Ataturk Training and Research Hospital, Katip Celebi University) Cakalagaoglu, Fulya (Department of Pathology, Ataturk Training and Research Hospital, Katip Celebi University) Tarhan, Mustafa Oktay (Department of Preventive Oncology, Institute of Oncology, Dokuz Eylul University)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제15권 제22호

발행연도: 2014.1

수록면: 9,739 - 9,745 (7page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Purpose: We aimed to evaluate the effects of hormone receptor, HER2, and epidermal growth factor receptor (EGFR) expression on epithelial ovarian cancer (EOC) prognosis and investigate whether or not phenotypic subtypes might exist. Materials and Methods: The medical records of 82 patients who were diagnosed with EOC between 2003 and 2012 and treated by platinum-based chemotherapy were retrospectively evaluated. Expression of EGFR, oestrogen (ER), progesterone (PR), and cerbB2 (HER2) receptors were assessed immunohistochemically on paraffin-embedded tissues of these patients. Three phenotypic subtypes were defined according to ER, PR, and HER2 expression and associations of these with EGFR expression, clinicopathologic features, platinum sensitivity, and survival were investigated. Results: When we classified EOC patients into three subtypes, 63.4% had hormone receptor positive (HR(+)) (considering breast cancer subtypes, luminal A), 18.3% had triple negative, and 18.3% had HER2(+) disease. EGFR positivity was observed in 37 patients (45.1%) and was significantly more frequent with advanced disease (p=0.013). However, no significant association with other clinicopathologic features and platinum sensitivity was observed. HER2(+) patients had significantly poorer outcomes than HER2(-) counterparts (triple negative and HR positive patients) (p=0.019). Multivariate analysis demonstrated that the strongest risk factor for death was residual disease after primary surgery. Conclusions: Triple negative EOC may not be an aggressive phenotype as in breast cancer. The HER2 positive EOC has more aggressive behaviour compared to triple negative and HR(+) phenotypes. EGFR expression is more frequent in advanced tumours, but is not related with poorer outcome. Additional ovarian cancer molecular subtyping using gene expression analysis may provide more reliable data.

#Ovarian carcinoma #receptor expression #phenotypes #prognosis

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요

이 논문의 저자 정보

Demir, Lutfiye

소속기관 Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital